Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 13,391

Document Document Title
WO/2012/142615A3
Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient i...  
WO/2013/012737A1
This invention provides new active compounds for pharmaceutical use including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma,...  
WO/2013/008062A1
The present invention relates to a non covalent molecular structure comprising a carbon nanostructure and a pyrene based glycoconjugate (I) which is linked to the said carbon nanostructure by a non covalent link, the said glycoconjugate ...  
WO/2012/088264A3
A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ colum...  
WO/2012/158965A3
Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based th...  
WO/2013/004086A1
Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated ...  
WO/2013/002346A1
Provided are: a (meth) allylsilane compound that is chemically bonded to a variety of alcohol derivatives such as saccharides and other polyol derivatives, is a raw material used to cause a substrate to express functionality such as anti...  
WO/2013/000275A1
Disclosed are compounds as shown as general formula (I), derivatives and uses thereof, wherein R1, R2, R3, R4, R5a, R5b, R5c and X have the definition as same as the description.  
WO/2012/071371A3
The disclosure relates to labeling glycans and glycosphingolipids from undefined mixtures with chemical moieties that emit light when exposed to electromagnetic radiation and uses of these labeled glycans and glycosphingolipids in microa...  
WO/2012/175813A1
This invention relates to synthetic oligo- or multivalent beta- 1 - 2 - linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell -mediated immune responses.  
WO/2012/173477A1
Title: Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable thereby. Abstract The invention relates to drug development and synthetic chemistry, in particul...  
WO/2012/172566A2
The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the pr...  
WO/2012/173942A2
Methods and materials for producing organic syringomycin, the methods include culturing a culture of Pseudomonas syringae and a growth medium including glucose, mannitol, histidine, a magnesium source, an iron source, and a buffer with a...  
WO/2012/167813A1
The present invention relates to a process, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, until a stationary growth phase is obtained, -cultivating said pre-cultivated cells in ...  
WO/2012/167920A1
The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related inventio...  
WO/2012/168325A1
The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, in absence of a...  
WO/2012/061662A9
Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells i...  
WO/2012/164062A1
The invention relates to triterpenes and triterpene glycosides of the formula (I) and/or physiologically acceptable salts thereof, preferably naturally occurring triterpenes and triterpene glycosides from Mycetia balansae and/or physiolo...  
WO/2012/139134A3
Described herein, at least in part, are methods of modulating oncogenic fusion proteins.  
WO/2012/163508A1
The invention relates to crystalline epirubicin hydrochloride and to a method for producing it. The method for producing crystalline epirubicin hydrochloride comprises the steps of (a) providing epirubicin hydrochloride, (b) preparing a ...  
WO/2012/164074A1
Compounds of the formula (I) (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are, independent of each other, hydrogen or a substituent as described in the specification, and one of RA, RB, RC and RD is P...  
WO/2012/161559A2
The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-densit...  
WO/2012/160337A1
Compounds which interact with HlsTONES Compounds of Formula I : • 4"'-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fucose [alpha]1-3 (4'-Sulfo-Fu- cose [alpha]1-4-Glucuronic acid [beta]1-0-Methyl or • 4" "-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fu...  
WO/2012/161250A1
Provided is an alpha-glucosidase which is easily obtainable and easily handled, and the enzyme activity of which is activated by an activator, and which effectively does not generate malto-oligosaccharides with a degree of polymerization...  
WO/2012/155916A1
The present invention relates to the synthesis of the tetrasaccharide of formula (I) and novel intermediates used in the synthesis.  
WO/2012/156273A1
A method for the manufacture an infant formula or an infant nutritional product comprising mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2 ...  
WO/2012/121862A3
The invention relates to valproic acid:dextran compounds and methods of using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including brain trauma, epilep...  
WO/2012/082650A3
The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present...  
WO/2012/146774A1
The present invention concerns a compound of formula (I) the salt, solvate, enantiomer, diastereoisomer and racemic mixture thereof for treating or preventing ischemia/reperfusion injury associated disorders during surgical operations or...  
WO/2012/140596A1
The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ph...  
WO/2012/140576A1
A compound of the formula (I) wherein R1 is a group removable by hydrogenolysis,and wherein R2 is OH or R2 is -NHR3 wherein R3 is a group removable by hydrogenolysis. The compound can be made from fructose by a Heyns-rearrangement. The c...  
WO/2012/073214A4
Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence.  
WO/2012/141228A1
Provided is a novel therapeutic means for Alzheimer's disease. A compound represented by general formula (I) [wherein Ar1 represents a 2-methoxy-4-(2-pyridylmethoxy)phenyl group or the like; and Ar2 represents a 1H-indole-6-yl group or t...  
WO/2012/142615A2
Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient i...  
WO/2012/093091A3
The present invention relates to saccharide mimics which show a better biological activity at low concentrations as known saccharide mimics in inhibiting angiogenesis and inhibiting formation of metastasis by inhibiting adhesion and/or m...  
WO/2012/132022A1
Provided is a compound represented by the formula (I): wherein R1 represents R5=N- (R5 represents a saccharide residue) or (R4 represents a mono- or polyethylene glycol residue); each of R2 and R3, whether identical or not, represents a ...  
WO/2012/129651A1
The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the com...  
WO/2012/119846A1
The present invention relates to synthetic lipoteicoic acid (LTA) mimeticswhich are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.  
WO/2012/121394A1
The present invention provides a substituted aromatic compound represented by general formula (I) [wherein A1, A2 and A3 independently represent an aryl group substituted by a hydrophilic group].  
WO/2012/121862A2
The invention relates to valproic acid:dextran compounds and methods of using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including brain trauma, epilep...  
WO/2012/122282A1
A preparation of antibiotic hygromycin B with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic hygromycin B with a purity of greater than 98% and impu...  
WO/2012/116447A1
A combination of a bacterial endotoxin, in particular a lipopolysaccharide, and a lipoteichoic acid for treating or preventing a metabolic disorder or bacterial infection, or for improving milk energy efficiency in a subject. The combina...  
WO/2012/049437A3
The invention relates to a method for transforming iota-carrageenan into alpha-carrageenan by means of a new class of 4S-iota-carrageenan sulfatase. The invention can be especially applied to the agro-food, pharmaceutical and cosmetic in...  
WO/2012/073214A3
Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence.  
WO/2012/113405A1
A method for the manufacture of a mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2. The use of compounds of general formula 1 and 2 in the m...  
WO/2012/094540A3
Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of a-galactosyl ceramides, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are pr...  
WO/2012/107204A1
The present invention relates to the use of the compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetness enhancer, to sweetener compositions comprising at least one sweetener and the compoun...  
WO/2012/107205A1
The present invention relates to the use of the compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetener and/or a sweetness enhancer, to sweetener compositions comprising the compound of for...  
WO/2012/104145A1
The present invention relates to an improved process for the preparation of an extract enriched in dihydrochalcones, and more specifically enriched in phlorizin, starting from a polyphenolic fraction originating from industrial apple pro...  
WO/2012/101605A1
The invention relates to the FGF receptor-activating oligosaccharides corresponding to formula (I) in which R1 represents an optionally substituted -O-alkyl group, R2 represents a hydroxyl group or an -O-alkyl group, R3, R5, R6, R7 and R...  

Matches 701 - 750 out of 13,391